BioSpace News Archive

Legend Biotech Corporation announced the U.S. Food and Drug Administration has approved CARVYKTI® for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, and an immunomodulatory agent, and are refractory to lenalidomide.

Biodesix, Inc. today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share.

Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM, the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy, at the 73rd Annual American College of Cardiology Scientific Session taking place from April 6, 2024 –April 8, 2024 in Atlanta, GA.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer vaccine.

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.

StageZero Life Sciences, Ltd. today announced further to its press release of April 2, 2024, that the Ontario Securities Commission (the “OSC”) has denied the Company’s application for a voluntary management cease trade order (the “MCTO”) as the Company does not meet the criteria for an MCTO.

Leash Biosciences today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.

Oxurion NV, a biopharmaceutical company headquartered in Leuven, made the following announcement regarding its financial calendar.

Taysha Gene Therapies, Inc. announced that, on April 1, 2024, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company’s common stock in connection with their employment.

Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in April.